Below are the most recent publications written about "Prostatic Neoplasms" by people in Profiles.
-
Nguyen NJ, Liu K, Lajkosz K, Iczkowski KA, van der Kwast TH, Downes MR. Addition of cribriform pattern 4 and intraductal prostatic carcinoma into the CAPRA-S tool improves post-radical prostatectomy patient stratification in a multi-institutional cohort. J Clin Pathol. 2025 Nov 19; 78(12):805-813.
-
Freedland SJ, Mulhall JP, Gleave M, De Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N. Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study. Eur Urol. 2025 05; 87(5):507-511.
-
Shore N, Armstrong AJ, Barata P, Byrne L, Hafron J, Young S, Paller C, Wise DR, Ventii K, Samadi A, Arangua P, Werahera PN, Lorentz J. Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice. Urology. 2025 05; 199:1-10.
-
Shore N, Nielsen SM, Esplin ED, Antonarakis ES, Barata PC, Beer TM, Beltran H, Bryce A, Cookson MS, Crawford ED, Dorff TB, George DJ, Heath EI, Helfand BT, Hussain M, Mckay RR, Morgans AK, Morris MJ, Paller CJ, Ross AE, Sartor O, Shen J, Sieber P, Smith MR, Wise DR, Armstrong AJ. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. JCO Oncol Pract. 2025 Jun; 21(6):747-753.
-
Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025 Jan 01; 131(1):e35612.
-
Bernhardt M, Weinhold L, Bremmer F, Chan E, Cheng L, Collins K, Downes M, Greenland N, Hommerding O, Iczkowski KA, Jufe L, Kreft T, van Leenders G, Oxley J, Perry-Keene J, Reis H, Schmid M, Tsuzuki T, Wobker S, Wiliamson SR, Kweldam C, Kristiansen G. Unexpectedly high variability in determining tumour extent in prostatic biopsies: implications for active surveillance. Histopathology. 2025 Mar; 86(4):627-639.
-
Shore ND, Morgans AK, Tutrone RF. Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(39):3179-3182.
-
Shore ND, Cookson MS, Efstathiou E. The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer. Future Oncol. 2024 Dec; 20(40):3351-3354.
-
Shakroo YM, Seabury CA, Iczkowski KA, Nelson K, Qian J, Ramnani DM. Germline pathogenic variants in prostate cancer. Pathol Res Pract. 2024 Dec; 264:155718.
-
La Cerda J, Thorley J, Sieber P, Cookson MS, Flanders SC, Gatoulis SC, Shore ND. Plain language review: the safety of relugolix combination therapy for advanced prostate cancer. Future Oncol. 2025 Jan; 21(1):51-62.